Itovebi

Inavolisib, the active ingredient in Itovebi, is a PI3K inhibitor presented as an oral formulation for prescription use. It targets cancers that rely on the PI3K/AKT/mTOR signaling pathway, offering a therapeutic option for patients with advanced solid tumours. GNH USA supplies Itovebi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Itovebi is a PI3Kα‑selective inhibitor used in oncology to address malignancies driven by the PI3K/AKT/mTOR pathway.

- Advanced solid tumours: helps control disease progression in patients with PI3K‑driven cancers. - Hormone‑receptor‑positive breast cancer: used in combination regimens to improve outcomes. - PI3K pathway‑mutated cancers: targets tumours with specific genetic alterations in the PI3Kα isoform.

Adverse reactions may occur with any antineoplastic therapy and should be monitored by the treating clinician.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: increased stool frequency. - Fatigue: reduced energy levels. - Rash: skin irritation or erythema. - Elevated liver enzymes: mild hepatic enzyme changes. - Hyperglycaemia: increased blood glucose levels.

Serious or Rare Side Effects: - Severe neutropenia: marked reduction in white blood cells. - Interstitial lung disease: inflammatory lung condition. - Severe hepatic dysfunction: significant liver injury. - Thromboembolic events: blood clot formation. - Severe hyperglycaemia: uncontrolled high blood sugar. - Life‑threatening allergic reactions: anaphylaxis.

Patients receiving Itovebi should be evaluated for potential risks and monitored throughout therapy.

- Baseline labs: obtain complete blood count, liver function tests, and fasting glucose before starting treatment. - Monitor glucose: regularly check blood sugar, especially in diabetic patients. - Liver function: assess hepatic enzymes periodically during therapy. - Infection risk: watch for signs of infection due to possible neutropenia. - Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Inavolisib may interact with other medicines that affect the same metabolic pathways or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Inavolisib plasma levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic exposure.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: risk of enhanced hyperglycaemia. - Other PI3K/AKT/mTOR inhibitors: additive toxicity. - Anticoagulants: potential for increased bleeding risk.